Introduction
============

Photodynamic therapy (PDT) is a minimally invasive therapeutic modality based on a photosensitizer (PS)-produced cytotoxic reactive oxygen species (ROS), prevalently singlet oxygen (^1^O~2~, SO), that holds great promise for treating various cancers [@B1]-[@B4]. By localizing light illumination to tumor regions, SO generation can be selectively restricted to a specific area to trigger tumor destruction and spare healthy organs through oxidation of the surrounding biomacromolecules [@B5]-[@B9]. In addition, the PDT can be combined with traditional chemotherapy to further improve the anticancer efficiency through different therapeutic mechanisms [@B10]-[@B12]. Specifically, the rapid development of nanotechnology has ensured the simultaneous integration of PS and chemotherapy drugs into the same nanoparticles to achieve combination therapy [@B13]-[@B16]. For instance, Dong et al. developed polyethylene glycol (PEG)-modified CaCO~3~ nanoparticles as a nanocarrier for the photosensitizer chlorin e6 and the chemotherapeutic drug doxorubicin (DOX) for cancer combination therapy [@B17]. Lin and coworkers reported a nanoscale coordination polymer-based nanoparticle carrying cisplatin and pyrolipid for combined chemotherapy and photodynamic therapy for resistant head and neck cancers [@B18].

Despite great promising, most current nanocarriers for chemo-photodynamic combination therapy are just used as a system to co-deliver the two agents. The encapsulated cytotoxic drug is gradually released within the tumor cells and directly kills the cells (chemotherapy), while the PS generates SO only under light irradiation to induce cell apoptosis (PDT) [@B19]-[@B21]. Therefore, these chemo-photodynamic therapies are simply combinations of the two therapies and do not confer synergistic effects of PS and chemotherapy drugs, making them insufficient for amplifying the anticancer efficacy. Increasing evidence has demonstrated that nanocarriers should boost the intracellular release of cytotoxic drug during the PDT process to yield the maximal benefit of chemo-photodynamic therapy [@B22]-[@B27]. Liu et al. demonstrated that the mesoporous silica nanorods with SO-sensitive shells offer remarkable synergistic therapeutic effects in cancer treatment owing to the boosted release of DOX specifically at the tumor site during the light-induced PDT process [@B28]. Zhang et al. observed that mesoporous silica nanoparticles (MSNs) with triggered self-accelerating DOX released during the light-induced PDT process with the MSN surface anchored by a SO-sensitive polymer induced more significant antitumor activity in human breast cancer than control MSNs [@B29]. Overall, these results suggested that simultaneous encapsulation of PS and chemotherapy drugs in the same nanocarriers is only a prerequisite for synergistic chemo-photodynamic therapy; triggering the intracellular release of chemotherapy drugs during the PDT process is necessary to realize cascade-amplifying synergistic therapeutic effects of chemo-photodynamic therapy.

Herein, to trigger drug release during the PDT process, SO-responsive PEGylated hyperbranched polyphosphates containing thioketal linkers (RHPPE) were successfully synthesized through (A2 + B3) type polycondensation (**Figure [S1](#SM0){ref-type="supplementary-material"}**) and then used to simultaneously encapsulate Ce6 and DOX (**Figure [1](#F1){ref-type="fig"}A**). The obtained Ce6 and DOX-loaded nanoparticles were denoted ^SO^HNP~Ce6/DOX~. Under 660-nm light irradiation, ^SO^HNP~Ce6/DOX~ can produce SO, which not only induces PDT against cancer but also realizes cleavage of the thioketal linkers to destroy nanoparticles. Disassembly of the nanoparticles subsequently boosts DOX release, thus activating a cascade of chemotherapeutic effects to synergistically destroy the remaining tumor cells after the initial round of PDT. Therefore, under the guidance of photoacoustic/magnetic resonance bimodal imaging, the ^SO^HNP~Ce6/DOX~ nanoparticles can be utilized to realize cascade-amplifying synergistic therapeutic effects of chemo-photodynamic therapy with high antitumor efficacy. This study provides new avenues for cascade-amplifying synergistic effects of chemo-photodynamic therapy by boosting drug release during the PDT process.

Results and discussion
======================

Preparation and characterization of ^SO^HNP~Ce6/DOX~
----------------------------------------------------

To substantiate our design, a PEGylated hyperbranched polyphosphate containing thioketal linkers (RHPPE) was first synthesized. As shown in **Figure [S1](#SM0){ref-type="supplementary-material"}**, RHPPE was obtained through a one-step reaction using hydroxyl-terminated mPEG, phosphorus oxychloride and 2,2\'-(propane-2,2-diylbis(sulfanediyl))bis(ethan-1-amine) (PDSE, **Figure [S2](#SM0){ref-type="supplementary-material"}**). The successful synthesis of RHPPE was confirmed by ^1^H (**Figure [S3](#SM0){ref-type="supplementary-material"}**) and ^13^C NMR (**Figure [S4](#SM0){ref-type="supplementary-material"}**); every resonance could be assigned to the protons of RHPPE. In addition, the SO non-responsive 1,7-diaminoheptane was used to replace PDSE to synthesize insensitive hyperbranched polyphosphate (HPPE) as a control (^1^H and ^13^C spectra are shown in **Figure [S5](#SM0){ref-type="supplementary-material"}-6**). Then, the photosensitizer Ce6 and the chemotherapy drug DOX were simultaneously integrated into RHPPE or HPPE through a nanoprecipitation method, and the resultant nanoparticles were denoted ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~, respectively. The average diameter of ^SO^HNP~Ce6/DOX~ was \~80 nm, similar to that of HNP~Ce6/DOX~ (**Figure [1](#F1){ref-type="fig"}B**). The UV-vis absorption spectra of ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ in aqueous suspension (**Figure [1](#F1){ref-type="fig"}C**) showed two characteristic absorption bands at approximately 490 nm and 660 nm, respectively. The loading contents (DLCs) of Ce6 and DOX for ^SO^HNP~Ce6/DOX~ were 3.39% and 3.13% (**Table [S1](#SM0){ref-type="supplementary-material"}**), respectively, which was similar to that of HNP~Ce6/DOX~. Additionally, ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ exhibited excellent stability in the culture media, and their size did not change for at least 120 h (**Figure [S7](#SM0){ref-type="supplementary-material"}**), which might be due to stabilization by the PEG layer.

The mechanism of boosted DOX release from ^SO^HNP~Ce6/DOX~ during the PDT process
---------------------------------------------------------------------------------

Based on our design, the light irradiation during the PDT process boosted the release of encapsulated DOX from ^SO^HNP~Ce6/DOX~. To verify this speculation, changes in DOX fluorescence of ^SO^HNP~Ce6/DOX~ at pH 7.4 and 5.5 were recorded upon 660-nm laser irradiation (0.2 W/cm^2^). DOX fluorescence was significantly elevated with an extension of the incubation time under 660-nm light irradiation at both pH conditions (**Figure [2](#F2){ref-type="fig"}A**). Considering that the fluorescence of DOX was partially quenched in ^SO^HNP~Ce6/DOX~ (**Figure [S8](#SM0){ref-type="supplementary-material"}**), the elevated DOX fluorescence intensity suggested that the light-induced PDT process boosted the release of encapsulated DOX from ^SO^HNP~Ce6/DOX~. Additionally, DOX release was further enhanced at pH 5.5 (the pH value of endosome/lysosomes), implying that the light-boosted DOX release was more efficient within tumor cells. The accelerated DOX release was more likely attributed to the increased DOX solubility at pH 5.5 [@B30], [@B31]. The light-boosted DOX release during the PDT process was further quantitatively evaluated (**Figure [2](#F2){ref-type="fig"}B**). Only approximately 8% of DOX was released from ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ at 24 h without light irradiation. In contrast, nearly 50% of DOX was released from ^SO^HNP~Ce6/DOX~ upon 660-nm laser irradiation (^SO^HNP~Ce6/DOX~ +L, 0.2 W/cm^2^, 30 min), while such boosted DOX release during the PDT process was not observed for HNP~Ce6/DOX~.

The boosted release properties of DOX from ^SO^HNP~Ce6/DOX~ during the PDT process was further evaluated under 660-nm laser irradiation at different power densities. As expected, less than 10% of DOX was released without 660-nm laser irradiation (**Figure [2](#F2){ref-type="fig"}C**). When ^SO^HNP~Ce6/DOX~ received 660-nm laser irradiation at power densities of 0.05 W/cm^2^, 0.1 W/cm^2^, and 0.5 W/cm^2^, approximately 22.92±3.26%, 47.24±3.08%, and 69.83±2.97% of DOX, respectively, was released from ^SO^HNP~Ce6/DOX~ at 24 h, thus exhibiting power density-dependent release behavior. Moreover, to simulate such boosted DOX release within the tumor cells, ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ were exposed to 660-nm laser at a power density of 0.2 W/cm^2^ for 10 min (L+, laser on) and then incubated for 2 h or 4 h in the dark (L-, laser off). As shown in **Figure [2](#F2){ref-type="fig"}D**, DOX release from ^SO^HNP~Ce6/DOX~ was improved under light irradiation and presented a pulsatile and controlled pattern during the laser on/laser off input cycle, while this phenomenon was insignificant for the HNP~Ce6/DOX~ control formulation.

Furthermore, the mechanism of such boosted DOX release during the PDT process was investigated. According to our design, SO was produced by the encapsulated Ce6 during the PDT process, and then the thioketal linkers were rapidly cleaved upon 660-nm light irradiation, which subsequently destroyed the structure of ^SO^HNP~Ce6/DOX~ and resulted in light-boosted DOX release. To verify this speculation, SO generation was first detected using 2′,7′-dichlorofluorescin diacetate (DCF-DA) as an indicator, because the green fluorescent signal of DCF was produced in the presence of SO [@B32]-[@B34]. Following 660-nm laser irradiation for 10 min, the fluorescence intensity change of blank nanoparticle ^SO^HNP and HNP groups was negligible (**Figure [3](#F3){ref-type="fig"}A**, Ex = 485 nm, Em = 525 nm). However, sharply increased DCF fluorescence was detected in the ^SO^HNP~Ce6~ and HNP~Ce6~ groups under 660-nm light irradiation, suggesting efficient production of SO by the encapsulated Ce6. In addition, the SO production of ^SO^HNP~Ce6~ was significantly attenuated in the presence of vitamin C (an ROS scavenger) [@B35], which further demonstrated that the SO was produced by the encapsulated Ce6 of ^SO^HNP~Ce6~ and HNP~Ce6~ under 660-nm laser irradiation.

Subsequently, we evaluated whether the produced SO was capable of rapidly cleaving the thioketal linkers of ^SO^HNP~Ce6~. As reported, the thioketal bond would be converted to two thiol terminal groups by SO, and thus, the degradation rate of ^SO^HNP could be calculated by measuring the amount of thiol groups by Ellman\'s test [@B36]-[@B38]. As shown in **Figure [3](#F3){ref-type="fig"}B**, under 660-nm laser irradiation, HNP~Ce6~ and ^SO^HNP degradation was not observed. Notably, the degradation of ^SO^HNP~Ce6~ was clearly detected, exhibiting laser density and time dependencies. For instance, more than 35% and 60% of the thioketal bonds were cleaved after receiving 660-nm laser irradiation for 60 min at power densities of 0.1 W/cm^2^ and 0.2 W/cm^2^. Additionally, the presence of vitamin C markedly decelerated the degradation rate, which could be attributed to the produced SO being scavenged by the vitamin C. Additionally, the cleavage of thioketal bonds was further verified by the ^1^H NMR spectra. As shown in **Figure [S9](#SM0){ref-type="supplementary-material"}**, the intensity of the resonance of thioketal protons (peak at \~1.52 ppm) decreased gradually with 660-nm laser irradiation. It was observed that 67.4% of the thioketal was degraded after 60 min of light irradiation through calculating the relative integration. Furthermore, the corresponding size and morphology changes were also analyzed by dynamic light scattering and transmission electron microscopy (**Figure [3](#F3){ref-type="fig"}C-D**). The light irradiation exhibited negligible effects on the size and microscopy of HNP~Ce6/DOX~. In contrast, the size of ^SO^HNP~Ce6/DOX~ remarkably increased to above 700 nm, which may be attributed to aggregation of the degraded HNP~Ce6/DOX~ particles.

Based on the above results, it can be concluded that the SO was produced by the encapsulated Ce6 during the PDT process under 660-nm light irradiation. The produced SO was not only realized PDT for cancer but was also capable of cleaving the thioketal linkers *in situ*, resulting in the rapid degradation and aggregation of ^SO^HNP~Ce6/DOX~, which consequently boosted DOX release from ^SO^HNP~Ce6/DOX~.

^SO^HNP~Ce6/DOX~ efficiently overcame drug resistance of cancer cells *in vitro*
--------------------------------------------------------------------------------

To demonstrate the advantage of the boosted DOX release during the PDT process in tumor cells, DOX-resistant MCF-7/ADR cells, which overexpressed P-glycoprotein (P-gp) protein to efflux a broad range of anticancer agents (e.g., DOX), were used to evaluate the subsequent anticancer efficacy [@B39]-[@B41]. The cellular uptake and retention of both ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ in MCF-7/ADR cells were first analyzed. MCF-7/ADR cells were incubated with free DOX, ^SO^HNP~Ce6/DOX~, and HNP~Ce6/DOX~ for 1 h, 2 h, 4 h, or 8 h, and the intracellular DOX content was then quantitatively determined according to our previously reported method [@B42], [@B43]. As shown in **Figure [4](#F4){ref-type="fig"}A**, the intracellular DOX content exhibited a time-dependent pattern and gradually elevated as the incubation time increased. At each time point, incubation of both ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ with MCF-7/ADR cells led to a significant accumulation of DOX in cells compared with free DOX. For instance, the intracellular DOX contents (normalized to total cellular protein) of the ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ groups were 2.304±0.174 and 2.458±0.131 μg/mg protein at 8 h, which were 3.92- and 4.18-fold greater, respectively, than that of free DOX (0.588±0.051 μg/mg protein). ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ enter into MCF-7/ADR cells *via* clathrin and caveolae-mediated endocytosis (**Figure [S10](#SM0){ref-type="supplementary-material"}**), which efficiently bypasses the efflux by P-gp [@B44]. In addition, the efflux of these formulations from MCF-7/ADR cells was also determined. MCF-7/ADR cells were incubated with ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ at a DOX concentration of 10 μg/mL for 6 h. In addition, to avoid the initial concentration effect, the free DOX group was elevated to 50 μg/mL. Subsequently, these formulations were replaced with fresh culture medium, and then, the intracellular DOX content was tracked. As shown in **Figure [4](#F4){ref-type="fig"}B**, almost 90% of the free drug was effluxed out of the cells after further incubation for 6 h, while 44.23% and 45.07% of the DOX was still retained within the DOX-resistant MCF-7/ADR.

Subsequently, we further evaluated whether such boosted DOX released during the PDT could be realized within tumor cells. For this aim, MCF-7/ADR cells were incubated with ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ for 1 h and then washed twice, exposed to 660-nm laser irradiation for 15 min, and collected for flow cytometry analysis. As shown in **Figure [4](#F4){ref-type="fig"}C**, without light irradiation, the ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ groups showed comparable intracellular fluorescence signals that were much higher than that of free DOX at each time point, which is in good agreement with the result shown in **Figure [4](#F4){ref-type="fig"}A**. The 660-nm laser irradiation did not remarkably increase the fluorescence intensity of DOX when MCF-7/ADR cells were treated with HNP~Ce6/DOX~ (HNP~Ce6/DOX~+L). In contrast, cells incubated with ^SO^HNP~Ce6/DOX~ plus 660-nm laser irradiation (^SO^HNP~Ce6/DOX~+L) exhibited significantly stronger intracellular fluorescence than those that did not receive 660-nm laser irradiation. As intracellular SO was generated after laser activation (**Figure [S11](#SM0){ref-type="supplementary-material"}**) and the fluorescence of DOX was partially quenched in ^SO^HNP~Ce6/DOX~ (**Figure [S8](#SM0){ref-type="supplementary-material"}**), the elevated DOX fluorescence intensity was due to the SO-enhanced release of DOX, demonstrating that the light-induced PDT process boosted the release of encapsulated DOX from ^SO^HNP~Ce6/DOX~.

Such boosted DOX release during the PDT process for ^SO^HNP~Ce6/DOX~ was further visualized with confocal laser scanning microscopy (CLSM). In the absence 660-nm laser irradiation, the fluorescence signals of DOX were mainly co-localized in lyso/endosomes when the cells were treated with HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ (**Figure [S12](#SM0){ref-type="supplementary-material"}**). After 660-nm laser irradiation, the DOX signal in the ^SO^HNP~Ce6/DOX~ group was mainly observed in cell nuclei (**Figure [4](#F4){ref-type="fig"}D**), which further verified that the light-induced PDT process boosted the release of encapsulated DOX from ^SO^HNP~Ce6/DOX~. In contrast, the light irradiation did not affect the co-localization of lyso/endosomes and DOX in the tumor cells, because of the inefficient DOX release from HNP~Ce6/DOX~ during the PDT process.

Rapid intracellular DOX release from nanoparticles has been demonstrated to be beneficial in terms of overcoming drug resistance. Based on the above results, it is reasonable to propose that such boosted intracellular DOX release during the PDT process could be beneficial in terms of enhancing the cancer cell-killing efficacy and overcoming drug resistance. Thereby, the anticancer efficacy of ^SO^HNP~Ce6/DOX~ and the controlled formulations against MCF-7/ADR cells were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MCF-7/ADR cells were incubated with the above-mentioned formulations for 12 h, washed with FBS-free medium, exposed to 660-nm laser irradiation, and further cultured for 12 h or 60 h for MTT assay (**Figure [5](#F5){ref-type="fig"}A-B**). As expected, free DOX at concentrations of 0.25, 0.5, 1 and 2 μg/mL exhibited no noticeable cytotoxicity to MCF-7/ADR cells at 24 h and 72 h. Similarly, treatment with HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ in the absence of 660-nm laser irradiation also showed negligible cytotoxicity. HNP~Ce6/DOX~ (HNP~Ce6/DOX~+L) showed moderately higher cytotoxicity after laser irradiation than without laser irradiation, which could be due to the PDT effect of the encapsulated Ce6. In addition, the cell viability was decreased to 80.46±6.31% (**Figure [5](#F5){ref-type="fig"}B**) at the highest DOX concentration at 72 h. In contrast, the ^SO^HNP~Ce6/DOX~ plus light irradiation (^SO^HNP~Ce6/DOX~+L) group exhibited much higher anticancer efficacy than the HNP~Ce6/DOX~+L group, and nearly 60% of MCF-7/ADR cells were destroyed at 72 h at the highest DOX concentration. Compared with the HNP~Ce6/DOX~+L group, the enhanced anticancer efficacy could be attributed to the boosted DOX released during the PDT process. In addition, it is worth noting that treatment with ^SO^HNP~DOX~ and HNP~DOX~ plus 660-nm light induced negligible toxicity and was biocompatible with the MCF-7/ADR cells (**Figure [S13](#SM0){ref-type="supplementary-material"}**). Moreover, the synergistic anticancer effect was further evaluated by determining cell apoptosis. Following staining with Annexin-V-FITC and propidine iodide (PI), incubation with ^SO^HNP~Ce6/DOX~ plus 660-nm irradiation induced the highest cell apoptosis (56.82%), while ^SO^HNP~Ce6/DOX~ without the light-activated drug release behavior did not promote cell apoptosis.

Pharmacokinetics and biodistribution of ^SO^HNP~Ce6/DOX~ *in vivo*
------------------------------------------------------------------

Encouraged by the superior anticancer efficacy of^SO^HNP~Ce6/DOX~ under 660-nm laser *in vitro*, we then carried out *in vivo* animal experiments to confirm our hypothesis that the boosted DOX release during the PDT process could significantly improve the anticancer efficacy. To evaluate the anticancer efficacy, the pharmacokinetics and biodistribution of ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ were first determined. It was clearly observed that HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ exhibited comparable pharmacokinetic curves, which significantly prolonged circulation compared with free DOX (**Figure [6](#F6){ref-type="fig"}A**). In comparison with free DOX, both nanoparticles significantly increased the area under the curve (AUC) by 12.53 and 11.26 orders of magnitude, respectively (**Table [S2](#SM0){ref-type="supplementary-material"}**). Additionally, ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ showed comparable DOX accumulation in tumor tissues at either 0.5 h, 1 h, 2 h, 6 h, 12 h or 24 h post-injection (**Figure [6](#F6){ref-type="fig"}B**) by using a Xenogen IVIS® Lumina system. After the mice were sacrificed, the total fluorescence counts in different organs from both groups were measured. A similar phenomenon was observed in that DOX accumulation in the main organ and tumor tissue was similar (**Figure [S14](#SM0){ref-type="supplementary-material"}**). The region-of-interest (ROI) analysis shown in **Figure [6](#F6){ref-type="fig"}C-D** further confirmed this result.

Precisely focusing the laser beam on the tumor area is critical for realizing the boosted DOX release during the PDT process. The tumor areas could be detected by photoacoustic (PA) and magnetic resonance (MR) bimodal imaging of ^SO^HNP~Ce6/DOX~. ^SO^HNP~Ce6/DOX~ with strong absorbance at 680 nm can be employed for *in vivo* PA imaging using a Nexus 128 PA imaging system. As shown in **Figure [7](#F7){ref-type="fig"}A, C**, intravenous injection of ^SO^HNP~Ce6/DOX~ exhibited significantly enhanced PA signals in the tumor tissue after 12 h post-injection; the quantitative results demonstrate that ^SO^HNP~Ce6/DOX~ exhibited a 2.87-fold higher PA signal at tumor sites 12 h post-injection. In addition, Ce6 has been demonstrated to be a chelating agent that captures Gd^3+^ for MR imaging [@B45], [@B46]. In comparison with commercial Magnevist^®^ (gadopentetate dimeglumine), the relaxivity (r~1~) of ^SO^HNP~Ce6-Gd/DOX~ and HNP~Ce6-Gd/DOX~ was increased to 13.08 mM^-1^s^-1^ (**Figure [S15](#SM0){ref-type="supplementary-material"}**), which was measured by using a 3T MRI scanner. At 12 h post-systemic injection of ^SO^HNP~Ce6-Gd/DOX~, the significantly enhanced T1 signals were observed at the tumor sites (**Figure [7](#F7){ref-type="fig"}B, D**). Collectively, based on PA and MR bimodal imaging, the 660-nm laser could be precisely focused on the tumor areas to boost DOX release from ^SO^HNP~Ce6/DOX~ during PDT process.

Under the guidance of PA and MR bimodal imaging, the *in vivo* anticancer efficacy of ^SO^HNP~Ce6/DOX~ under 660-nm laser irradiation was subsequently evaluated in MCF-7/ADR tumor-bearing mice. A total of 35 tumor-bearing mice were randomly divided into seven groups (n = 5). Various samples were administered via the tail vein at a DOX concentration of 2.5 mg/kg or a Ce6 concentration of 2.0 mg/kg. Under the guidance of the PA and MR bimodal imaging, the tumor tissue was precisely irradiated with 660-nm laser light 12 h post-injection. The tumor sizes were monitored over the following 16 days (**Figure [8](#F8){ref-type="fig"}A**). Treatment with free DOX did not show tumor growth inhibition compared with PBS treatment due to the DOX resistance of MCF-7/ADR tumor xenografts. Administration of HNP~Ce6/DOX~ without laser irradiation slightly induced tumor growth inhibition, and treatment with HNP~Ce6/DOX~ with 660-nm laser irradiation (HNP~Ce6/DOX~ +L) led to slight inhibition of tumor growth because of the PDT effect. In contrast, treatment with ^SO^HNP~Ce6/DOX~ plus laser irradiation (^SO^HNP~Ce6/DOX~+L) resulted in the highest inhibition efficacy toward tumor growth (*p* \< 0.05), while the ^SO^HNP~Ce6~ plus laser irradiation (^SO^HNP~Ce6~+L, PDT effect) and ^SO^HNP~Ce6/DOX~ without laser irradiation (chemotherapy) groups only mildly inhibited tumor growth, indicating that the boosted DOX release during the PDT process could significantly induce cascade-amplifying synergistic effects of chemo-photodynamic therapy. The boosted DOX released from ^SO^HNP~Ce6/DOX~ was capable of arousing a cascade of chemotherapy to synergistically destroy the remaining tumor cells after previous PDT, thus realizing the synergistic therapeutic effects of chemo-photodynamic therapy with great antitumor efficacy.

In addition, inspection of the tumor weight in **Figure [8](#F8){ref-type="fig"}B** after treatment also indicated that the ^SO^HNP~Ce6/DOX~+L group exhibited the highest anticancer effect among these formulations. Furthermore, the immunohistochemical studies of tumor slices were highly supportive of the anticancer effect after the treatment (**Figure [S16](#SM0){ref-type="supplementary-material"}**). Extensive regions of apoptotic (TUNEL-positive) and non-proliferative cells (Ki67-negative) were observed in mice treated with ^SO^HNP~Ce6/DOX~+L. It should be noted that the body weight of the mice treated with these formulations showed no noticeable change during the therapeutic period (**Figure [8](#F8){ref-type="fig"}C**). Furthermore, the hematoxylin and eosin (H&E) stained images of major organs (**Figure [S17](#SM0){ref-type="supplementary-material"}**) and the analysis of alanine aminotransferase, aspartate aminotransferase and blood urea nitrogen (**Figure [8](#F8){ref-type="fig"}D**) also demonstrated that polyphosphate-based ^SO^HNP~Ce6/DOX~ had no obvious toxicity to the liver and kidney. In comparison with the control group, hematological assessment (**Figure [S18](#SM0){ref-type="supplementary-material"}**) showed no significant differences among all the examined parameters after ^SO^HNP~Ce6/DOX~+L treatment, suggesting that ^SO^HNP~Ce6/DOX~ enhanced the therapeutic efficacy toward MCF-7/ADR tumors without obvious side effects.

Conclusion
==========

We successfully synthesized an SO-responsive hyperbranched polyphosphate and then used this polymer to simultaneously encapsulate Ce6 and DOX to confer cascade-amplifying synergistic therapeutic effects of chemo-photodynamic therapy. The obtained nanocarrier ^SO^HNP~Ce6/DOX~ can produce SO under 66-nm light irradiation, which not only can induce tumor cell death through the PDT effect but can also rapidly destroy the structure of ^SO^HNP~Ce6/DOX~. The disassembled nanoparticles subsequently boosted DOX release during the light-induced PDT process *in vitro* and *in vivo*, thus activating cascaded chemotherapy to synergistically destroy the remaining tumor cells after the initial round of PDT. In addition, the nanocarrier ^SO^HNP~Ce6/DOX~ could also precisely detect the tumor area by PA and MR bimodal imaging. Under the guidance of bimodal imaging, the ^SO^HNP~Ce6/DOX~ realized cascade-amplifying synergistic therapeutic effects of chemo-photodynamic therapy, resulting in superior anticancer activity even in the DOX-resistant tumor model. This study provides a promising avenue for cascade-amplifying therapeutic effects of chemo-photodynamic therapy.

Methods
=======

Materials and characterization
------------------------------

Monomethoxy poly(ethylene glycol) (mPEG, Sigma-Aldrich Chemical) with a molecular weight of 2000 was dried by azeodistillation of anhydrous toluene twice before use. Phosphorus oxychloride (Xiya Reagent) was distilled under reduced pressure just before use. Chloroform (CHCl~3~) was obtained from Duksan Pure Chemicals Co., Ltd. (Korea) and purified through a Vigor solvent purification system. 1,7-Diaminoheptane was purchased from TCI Shanghai Development Co., Ltd. 3-(4,\[zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was purchased from Sigma-Aldrich Chemical Co., Ltd. Chlorin e6 (Ce6) was obtained from J&K Chemical Ltd. Doxorubicin (DOX) was purchased from Wuhan Dahua Co. Ltd. All other reagents and solvents were of analytical grade and used as received.

The proton nuclear magnetic resonance (^1^H NMR) spectra were recorded in deuterated dimethyl sulfoxide (DMSO-*d~6~*) on a 400-MHz spectrometer (Avance Ш, Bruker, Germany). The size and zeta potential measurements were carried out in aqueous solution using a Malvern ZS90 dynamic light scattering instrument with a He-Ne laser (633 nm) and 90° collecting optics. The data were analyzed using Malvern Dispersion Technology Software 5.10. Transmission electron microscopy (TEM) measurements were made using a JEOL 2010 high-resolution transmission electron microscope with an accelerating voltage of 200 kV. The concentrations of Ce6 and DOX were determined by Agilent high-performance liquid chromatography (HPLC) according to previous methods [@B42], [@B47].

Cell lines and animals
----------------------

The human breast adenocarcinoma (MCF-7) cell line was obtained from the American Type Culture Collection (ATCC, MD, USA), and the P-gp overexpressing human breast carcinoma cell line (DOX-resistant MCF-7 cell line, MCF-7/ADR) was kindly provided by Prof. Jun Wang (University of Science and Technology of China). Both cell types were cultured in RPMI 1640 medium (Gibco, China) supplemented with 10% fetal bovine serum (FBS, ExcellBio, China) at 37 °C using a humidified 5% CO~2~ incubator. MCF-7/ADR cells were maintained with free DOX at 5 μg/mL. BALB/c nude mice (female, 6 weeks old) and ICR mice (6 weeks old) were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All animals received care in compliance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals, and all procedures were approved by the Tianjin Medical University Animal Care and Use Committee. The xenograft tumor model was generated by injection of 5×10^6^ MCF-7/ADR cells (100 μL) with 50% Matrigel^®^ Matrix (Corning, Bedford, MA) into the mammary fat pad of female BALB/c nude mice.

Synthesis of PDSE
-----------------

In a typical reaction, a mixture of cysteamine hydrochloride (11.36 g, 100 mmol) and anhydrous acetone (15.6 g, 269 mmol) were saturated with dry hydrogen chloride and stirred at room temperature for 8 h. After the reaction, the product was filtered and washed twice with chloroform. Then, the product was dried and recrystallized from 6 M NaOH aqueous solution three times. Finally, the product was extracted with CH~2~Cl~2~ to obtain the product (6.33 g, 65% yield).

Synthesis of SO-responsive hyperbranched copolymer
--------------------------------------------------

Anhydrous mPEG (0.500 g, 0.25 mmol) was dissolved in 10 mL dry chloroform, and phosphorus oxychloride (0.450 g, 2.93 mmol) in 10 mL of CHCl~3~ was then added. After stirring for 2 h at 25 ºC, the mixture was added slowly to a CHCl~3~ solution of PDSE (1 g, 5.2 mmol) and triethylamine (1.26 g, 12.5 mmol) at -5 ºC. After reaction for 12 h, the salts were removed by filtration, and the liquid phase was washed by dilute hydrochloric acid (1 M), saturated NaHCO~3~ aqueous solution and saturated brine. The organic phase was separated, collected, dried with magnesium sulfate anhydrous and precipitated into anhydrous diethyl ether at 0 ºC twice. The obtained product was dried to give a pale-yellow powder with a typical yield of approximately 79%. The non-responsive hyperbranched copolymer was synthesized by a similar method while the PDSE was replaced by 1,7-diaminoheptane.

Preparation of nanoparticles
----------------------------

The corresponding nanoparticles were fabricated using a solvent exchange method. Briefly, 10 mg RHPPE or HPPE was dissolved in 0.5 mL DMSO. Under moderate stirring, 5 mL ultrapurified water (Millipore Milli-Q Synthesis, 18.2 MΩ) was immediately added. The mixture was stirred for 15 min at ambient temperature, followed by dialysis to remove the organic solvents (Spectra/Por, Float-A-Lyzer, MWCO 3500). The obtained nanoparticles were denoted ^SO^HNP or HNP, respectively. For Ce6/DOX loading, 10 mg RHPPE or HPPE were mixed with 1 mg DOX and 1 mg Ce6 in 0.5 mL DMSO, and 5.0 mL H~2~O was immediately added. The DMSO was removed by dialysis. After centrifugation at 3000 ×g to remove unencapsulated photosensitizer/drug, the obtained nanoparticles were denoted ^SO^HNP~DOX/Ce6~ or HNP~DOX/Ce6~, respectively. The DLC and encapsulation efficiency (EE) of Ce6 and DOX were determined by the UV-vis method at 660 nm and 490 nm after the lyophilized nanoparticles were dissolved in DMSO.

Production of SO under 660-nm laser irradiation
-----------------------------------------------

The generation of SO from Ce6-loaded nanoparticles under laser irradiation was detected by dichlorofluorescein diacetate. [@B28] First, ^SO^HNP~Ce6~, HNP~Ce6~ and ^SO^HNP were prepared as described above and incubated in phosphate buffer (PB, 20 mM) at pH 7.4. Second, 1.0 mL dichlorfluorescein diacetate in ethanol was mixed with 4.0 mL NaOH aqueous solution (10 mM) for 1 h at room temperature. Then, the mixture was transferred to the PBS containing nanoparticles on ice. The nanoparticles in the above solution were exposed to 660-nm laser with a power density of 0.2 W/cm^2^. The emission fluorescence change at 525 nm was recorded when excited at 485 nm.

Degradation measurements of nanoparticles
-----------------------------------------

^SO^HNP~Ce6~, HNP~Ce6~ and ^SO^HNP prepared as described above were suspended in phosphate buffer at pH 7.4 at a Ce6 concentration of 2.5 μg/mL. The nanoparticles were then exposed to 660-nm laser with the power density of 0.2 W/cm^2^. The degradation rate at 10, 20, 30, 40, 50 and 60 min were detected by the 5,5\'-dithiobis(2-nitrobenzoic acid) (DTNB) method, as reported in a previous study [@B48].

DOX release*in vitro*
---------------------

The doxorubicin release profiles from ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ *in vitro* were studied in a buffer solution at pH 7.4 or 5.5, respectively. DOX-loaded nanoparticles were transferred into a dialysis tube and immersed in 15 mL buffer at 37 °C. At the predetermined time, the inner buffer was irradiated by 660-nm laser (0.2 W/cm^2^), and the external buffer was collected to measure the concentration of DOX via HPLC analysis after lyophilization. The tube was immersed in fresh buffer prewarmed to 37 °C for further release experiments.

Cellular internalization of nanoparticles *in vitro*
----------------------------------------------------

MCF-7/ADR cells were seeded in 24-well plates at a density of 5 × 10^4^ cells per well in 0.5 mL RPMI 1640 medium overnight. DOX, ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ were incubated at pH 7.4 for 2 h, washed twice with cold PBS and harvested by trypsin treatment. The harvested cells were further washed twice with PBS by centrifuging at 152 ×g for 5 min at 4 °C. After two cycles of washing and centrifugation, the intracellular fluorescence of DOX was detected by flow cytometry (BD FACSVerse). Additionally, cells treated with DOX, ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ were similarly washed with cold PBS twice and lysed with 1% Triton X-100 in PBS (250 μL) at 37 °C for 30 min, followed by three freeze-thaw cycles. The concentration of DOX in the cell lysates was measured by HPLC, which was normalized to the total cellular protein content determined by a BCA Protein Assay Kit (Pierce, Rockford, IL).

Laser-triggered intracellular drug release *in vitro*
-----------------------------------------------------

MCF-7/ADR cells were seeded in 24-well plates at a density of 5 × 10^4^ cells per well in 0.5 mL RPMI 1640 medium overnight. ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ were incubated at pH 7.4 for 2 h. Then, the medium was replaced with fresh RPMI 1640 medium, and the cells were irradiated by 660-nm laser for 15 min. After irradiation, the cells were further incubated at 37 °C for 2 h, washed twice with cold PBS and harvested by trypsin treatment. The harvested cells were further washed twice with PBS by centrifuging at 152 ×g for 5 min at 4 °C. After two cycles of washing and centrifugation, the intracellular fluorescence of DOX was detected by flow cytometry.

For CLSM observations, MCF-7/ADR cells were seeded onto 12-mm coverslips in 24-well plates with 20,000 cells per well in 0.5 mL RPMI 1640 medium and incubated in a humidified 5% CO~2~ atmosphere for 12 h. ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ were incubated at pH 7.4 for 2 h. Then, the medium was replaced with fresh RPMI 1640 medium without nanoparticles, and the cells were irradiated by a 660-nm laser for 15 min. After irradiation, the cells were further incubated at 37 °C. After 2 h of incubation, the cells were washed with cold PBS and fixed with 4% paraformaldehyde for 15 min at room temperature; they were then stained with Lysotracker^TM^ Green (Invitrogen, Carlsbad, CA) and 4ʹ,6-diamidino-2-phenylindole (DAPI) sequentially following the standard protocol of the manufacturer before imaging on an Olympus FV1200 confocal microscope.

*In vitro* cytotoxicity
-----------------------

MCF-7/ADR cells were seeded in 96-well plates at 5000 cells per well in 100 µL complete 1640 medium supplemented with 10% FBS. Subsequently, the cells were incubated with 1640 medium containing ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ with different concentrations of DOX for 12 h. Then, the culture medium was replaced with fresh complete 1640 medium at pH 7.4 and exposed to light irradiation with a power density of 0.1 W/cm^2^ for 30 min. After irradiation, the cells were further incubated at 37 °C for 12 or 60 h, and MTT stock solution was added to the wells to achieve a final concentration of 1 mg/mL. After incubation for another 2 h, 100 µL extraction buffer (20% SDS in 50% *N,N*-dimethylformamide, pH 4.7, prepared at 37 °C) was added and incubated overnight at 37 °C. The absorbance was measured at 570 nm using a Bio-Rad 680 microplate reader (Bio-Rad, USA). Cell viability was normalized to that of cells cultured in the culture medium with PBS treatment, which served as the indicator of 100% cell viability.

Apoptosis assay
---------------

MCF-7/ADR cells were seeded in the 12-well plates (10×10^4^ cells/well). After incubation at 37 °C overnight, the medium was replaced with fresh RPMI 1640 medium containing DOX, ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ (\[DOX\] = 2 μg/mL). After incubation for 12 h, MCF-7/ADR cells were washed twice with PBS and exposed to 660-nm laser at a power of 0.1 W/cm^2^ for 30 min. The cells were further incubated for 60 h, collected and treated using an Annexin V-FITC apoptosis detection kit I (BD Biosciences) according to the manufacture\'s procedure.

Pharmacokinetic studies
-----------------------

Female 6-week-old ICR mice were used to study the pharmacokinetics of ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~. DOX-loaded ^SO^HNP~Ce6/DOX~ and HNP~Ce6/DOX~ in PBS (0.01 M, pH 7.4) were injected intravenously into the tail vein at an equivalent dose of 10 mg DOX per kg of mouse body weight (n = 5 for each group). After a predetermined time (0.167, 0.5, 1, 2, 6, 12, 24 and 48 h), blood samples were collected from the retro-orbital plexus of the mouse eye, and 100 μL of plasma was obtained. The concentration of DOX in the plasma was analyzed according to previously reported method. [@B43]

Biodistribution of ^SO^HNP~Ce6/DOX~ *in vivo*
---------------------------------------------

Following intravenous injection of ^SO^HNP~Ce6/DOX~ into nude mice bearing MCF-7/ADR xenografts, the *in vivo* fluorescence distribution in tumor-bearing mice was detected at predetermined time points by using a Xenogen IVIS® Lumina system (Caliper Life Sciences, USA). At 24 h post-injection, the mice were sacrificed, and the solid tumor tissues were collected, washed with PBS, and imaged by the Xenogen IVIS Lumina system. The quantitative distribution of DOX in various tissues was detected according to the previous method. [@B43]

Furthermore, to evaluate *in vivo* tumor PA/MR imaging, ^SO^HNP~Ce6/DOX~ at the dose of 5 mg/kg Ce6 was intravenously injected into the mice bearing MCF-7/ADR tumors. Then, the tumor region of the mice was observed using an Endra Nexus 128 with an excitation wavelength of 680 nm or a 3.0 T clinical MR system with a small animal receiver coil (GE Signa Excite). The imaging intensity at the tumor was analyzed at different time points. The statistical differences were analyzed using *t*-tests, where a P value of \<0.05 was considered significant.

Tumor growth inhibition *in vivo*
---------------------------------

The mice bearing the MCF-7/ADR xenograft were divided randomly into seven groups and received an intravenous injection once a week of PBS, free DOX (2.5 mg/kg), ^SO^HNP~Ce6/DOX~, HNP~Ce6/DOX~ (equivalent DOX dose of 2.5 mg/kg) or ^SO^HNP~Ce6~ (equivalent Ce6 dose of 2.0 mg/kg) when the tumor volume was approximately 50 mm^3^. Tumor growth was monitored every 2 days using calipers to measure the perpendicular diameters. The tumor volume was calculated using the following formula: tumor volume = 0.5 × length × width^2^.

The day after the last evaluation time point, the tumor tissue was excised and fixed with 4% paraformaldehyde overnight at 4 °C and embedded in paraffin for analysis. The tissue sections (6 μm) were stained with H&E. Paraffin-embedded 5-μm tumor sections were obtained for terminal transferase dUTP nick end labeling (TUNEL) or Ki67 assay immunohistochemical staining.

*In vivo* toxicity studies
--------------------------

Mice were treated daily with various formulations at a dose of 2.5 mg/kg DOX for three days, and then euthanized on day 4. Serum was collected and mouse alanine aminotransferase (ALT), aspartate transaminase (AST) and blood urea nitrogen (BUN) were measured using quantitative enzyme-linked immunosorbent assay (ELISA) kits, following validation of each ELISA kit, according to the manufacturer\'s instructions. Absorbance was read using a Bio-Rad microplate reader (Hercules, CA, USA) at 450 nm.

For organ damage analysis, mice were euthanized after the ELISA study, and major organs were collected and fixed in 4% (w/v) PBS-buffered paraformaldehyde overnight and finally embedded in paraffin. The paraffin-embedded organ tissues were cut to a thickness of 5 µm, stained with H&E and observed by optical microscope (Nikon, TE2000U).

Statistical analysis
--------------------

The statistical significance of treatment outcomes was assessed using Student\'s *t*-test (two-tailed); *p* \< 0.05 was considered statistically significant in all analyses (95% confidence level).
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![**(A)** Schematic illustration of ^SO^HNP~Ce6/DOX~ with PDT-activated cascade chemotherapy to synergistically treat cancer cells. The PS-generated SO would selectively cleave the thioketal linkers under 660-nm laser irradiation, leading to nanoparticle destruction and triggering DOX release into the cell nuclei. **(B)** Hydrodynamic diameters of HNP~Ce6/DOX~ or ^SO^HNP~Ce6/DOX~. **(C)** The UV-Vis absorption spectra of free Ce6, free DOX, HNP, ^SO^HNP, HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~.](thnov08p2939g001){#F1}

![**(A)** Fluorescence recovery of DOX after light irradiation at pH 7.4 or 5.5. **(B)** The cumulative release of DOX from HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ with or without light irradiation. **(C)** The cumulative release of DOX from ^SO^HNP~Ce6/DOX~ upon 660-nm laser irradiation at different power densities for 30 min. **(D)** Laser-stimulated pulsed release of DOX from HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ at pH 5.5. The samples were irradiated with 660-nm laser for 10 min at different time points indicated by the arrows.](thnov08p2939g002){#F2}

![**(A)** Fluorescence intensity changes of DCF at 525 nm in different groups (PBS, Ce6 in PBS after irradiation, ^SO^HNP in PBS after irradiation, HNP~Ce6~ in PBS after irradiation and ^SO^HNP~Ce6~ in PBS after irradiation). Vitamin C acts as an ROS scavenger. **(B)** The degradation rates of ^SO^HNP, HNP~Ce6~ and ^SO^HNP~Ce6~ after irradiation with different power densities (L: 0.2 W/cm^2^, L\': 0.1 W/cm^2^) detected by Ellman\'s test. **(C)** Changes in HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ diameter after light irradiation. **(D)** Transmission electron microscopy images of HNP~Ce6/DOX~ and ^SO^HNP~Ce6/DOX~ with or without light irradiation. The scale bar is 200 nm.](thnov08p2939g003){#F3}

![**(A)** Total intracellular DOX in MCF-7/ADR cells after incubation with free DOX, HNP~Ce6/DOX~, or ^SO^HNP~Ce6/DOX~ for 1, 2, 4 or 8 h. The dose of DOX (free DOX or equivalent) was 4 μg/mL in the cell culture. \**p* \< 0.05. **(B)** Retention of DOX in MCF-7/ADR cells after preincubation with DOX, ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~. The concentration of total DOX in the free DOX preincubation was 50 μg/mL, while it was 10 μg/mL in the ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~ groups. \**p* \< 0.05 compared with HNP~Ce6/DOX~ or ^SO^HNP~Ce6/DOX~. **(C)** Geometric mean fluorescence intensity (GMFI) of MCF-7/ADR cells after treatment with free DOX, HNP~Ce6/DOX~, HNP~Ce6/DOX~ plus laser, ^SO^HNP~Ce6/DOX~ or ^SO^HNP~Ce6/DOX~ plus laser. The power density of the 660-nm laser was 0.1 W/cm^2^. Data were collected from flow cytometric analyses (n = 3). \**p* \< 0.05. **(D)** Assessment of the intracellular DOX release and biodistribution of HNPCe6/DOX or SOHNPCe6/DOX in MCF-7/ADR cells with continuous 660-nm laser irradiation (0.1 W/cm^2^) (scale bar: 50 μm). The concentration of DOX in the cell culture was 6 μg/mL. Acidic endosomes/lysosomes and cell nuclei were stained with LysoTracker^TM^ Green (green) and DAPI (blue), respectively.](thnov08p2939g004){#F4}

![Cytotoxicity of DOX, HNP~Ce6/DOX~, or ^SO^HNP~Ce6/DOX~ against MCF-7/ADR cells. The cells were incubated with nanoparticles for 12 h. After laser exposure for 30 min, the cells were further incubated with fresh medium for 12 h **(A)** or 60 h **(B)**. The laser power density was 0.1 W/cm^2^. \**p* \< 0.05. **(C)** Flow cytometry analysis of MDA-MB-231 cell apoptosis induced by different formulations based on Annexin V-FITC/PI staining. Early apoptotic cells are shown in the lower right quadrant, and late apoptotic cells are shown in the upper right quadrant.](thnov08p2939g005){#F5}

![**(A)** Pharmacokinetic profiles of DOX after intravenous administration of different DOX formulations (mean±SD, n = 4). **(B)** *In vivo* fluorescence images of the MCF-7/ADR tumor-bearing mice at 0.5, 1, 2, 6, 12 and 24 h after *i.v.* injection of ^SO^HNP~Ce6/DOX~ or HNP~Ce6/DOX~. The tumor site was circled with a white line. Semiquantitative biodistribution of ^SO^HNP~Ce6/DOX~ **(C)** and HNP~Ce6/DOX~ **(D)** in various organs at 24 h determined by the Ce6 fluorescence intensity. The data are shown as the mean±SD.](thnov08p2939g006){#F6}

![**(A)** PA imaging of tumor regions imaged before and 12 h post-injection of ^SO^HNP~Ce6/DOX~ nanoparticles. The tumor site was circled with a white line. **(B)** *T~1~*-weighted tumor contrast enhancement before and 12 h post-injection of ^SO^HNP~Ce6/DOX~ nanoparticles. The tumor site was circled with a white line. Semiquantitative analysis of the PA **(C)** and MR signal **(D)** in the tumor site, as performed in (A) and (B). \**p* \< 0.05.](thnov08p2939g007){#F7}

![**(A)** Tumor growth inhibition in MCF-7/ADR tumor xenograft-bearing nude mice after different treatments (n = 5). The injections were performed on days 0, 7 and 14 with an equivalent DOX dose of 2.5 mg/kg or a Ce6 dose of 2.0 mg/kg (mean±SD, n = 5). \**p* \< 0.05. **(B)** The weight of the MCF-7/ADR xenograft tumor mass excised after the treatment. **(C)** Body weight monitoring of the mice that received treatment with various samples. **(D)** Enzyme-linked immunosorbent examination of mouse alanine aminotransferase (ALT, U/L), aspartate transaminase (AST, U/L) and blood urea nitrogen (BUN, 10 μmol/L) in the serum after receiving different treatments. \**p* \< 0.05, vs. DOX.](thnov08p2939g008){#F8}
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